Investments

Barclays Boosts Cirrus Logic Price Target to $120.00

8 days ago   |   By ETF Daily News

Cirrus Logic had its target price increased by Barclays from $100.00 to $120.00 in a report published on Wednesday, Analyst Ratings Network reports. Barclays currently has an overweight rating on the semiconductor company's stock.
Several other analysts also recently weighed in on CRUS. Susquehanna reaffirmed a buy rating and issued a $114.00 target price on shares of Cirrus Logic in a report on Tuesday, November 2nd. Zacks Investment Research downgraded shares of Cirrus Logic from a buy rating to a hold rating and set a $99.00 target price on the stock. in a report on Tuesday, January...
Read more ...

 

Northland Securities Trims Esperion Therapeutics Target Price to $5.00

Northland Securities Trims Esperion Therapeutics Target Price to $5.00

8 days ago   |   By ETF Daily News

Esperion Therapeutics had its price objective trimmed by Northland Securities from $10.00 to $5.00 in a report issued on Wednesday, The Fly reports.
ESPR has been the topic of several other reports. Morgan Stanley downgraded shares of Esperion Therapeutics from an equal weight rating to an underweight rating and dropped their price objective for the company from $17.00 to $11.00 in a report on Thursday, October 14th. Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $20.00 to $12.00 and set a buy rating on the stock in a report on Thursday, December...
Read more ...

 

B. Riley Boosts Comerica Price Target to $100.00

B. Riley Boosts Comerica Price Target to $100.00

8 days ago   |   By ETF Daily News

Comerica had its target price hoisted by B. Riley from $87.00 to $100.00 in a report released on Wednesday, The Fly reports. B. Riley also issued estimates for Comerica's FY2021 earnings at $8.30 EPS, Q2 2022 earnings at $1.58 EPS, Q3 2022 earnings at $1.60 EPS, Q4 2022 earnings at $1.84 EPS, FY2022 earnings at $6.35 EPS, Q1 2023 earnings at $1.71 EPS, Q2 2023 earnings at $1.81 EPS, Q3 2023 earnings at $2.07 EPS, Q4 2023 earnings at $2.11 EPS and FY2023 earnings at $7.70 EPS.
CMA has been the subject of several other reports. Robert W. Baird lowered Comerica from a neutral rating to an...
Read more ...

 

Solo Brands Stock Rating Upgraded by Citigroup

Solo Brands Stock Rating Upgraded by Citigroup

8 days ago   |   By ETF Daily News

Citigroup upgraded shares of Solo Brands from a neutral rating to a buy rating in a research report sent to investors on Wednesday morning, Analyst Price Targets reports. The firm currently has $20.00 target price on the stock, up from their previous target price of $17.00.
Several other research firms have also recently issued reports on DTC. William Blair assumed coverage on Solo Brands in a research report on Monday, November 22nd. They issued an outperform rating on the stock. Piper Sandler assumed coverage on Solo Brands in a research report on Monday, November 22nd. They issued an...
Read more ...

 

DigitalOcean PT Lowered to $85.00

DigitalOcean PT Lowered to $85.00

8 days ago   |   By ETF Daily News

DigitalOcean had its price objective cut by Barclays from $120.00 to $85.00 in a research note published on Wednesday morning, The Fly reports.
Several other equities analysts have also commented on the stock. Oppenheimer upped their price target on shares of DigitalOcean from $100.00 to $130.00 and gave the stock an outperform rating in a research report on Monday, November 8th. William Blair assumed coverage on shares of DigitalOcean in a research report on Friday, November 12th. They set an outperform rating for the company. upped their price target on shares of DigitalOcean from $65.00...
Read more ...

 

Campbell Soup PT Raised to $45.00

Campbell Soup PT Raised to $45.00

8 days ago   |   By ETF Daily News

Campbell Soup had its target price lifted by Morgan Stanley from $44.00 to $45.00 in a research report sent to investors on Tuesday morning, The Fly reports. Morgan Stanley currently has an equal weight rating on the stock.
Several other equities research analysts have also issued reports on CPB. Citigroup decreased their target price on Campbell Soup from $47.00 to $45.00 and set a neutral rating for the company in a research report on Tuesday, October 5th. Credit Suisse Group lifted their price objective on Campbell Soup from $41.00 to $43.00 and gave the stock a neutral rating in a...
Read more ...

 

Robert W. Baird Lowers Quest Diagnostics Price Target to $162.00

Robert W. Baird Lowers Quest Diagnostics Price Target to $162.00

8 days ago   |   By ETF Daily News

Quest Diagnostics had its target price cut by Robert W. Baird from $173.00 to $162.00 in a research report issued on Thursday, The Fly reports. Robert W. Baird's target price would suggest a potential upside of 13.84% from the company's previous close.
A number of other equities analysts have also recently issued reports on the company. Morgan Stanley dropped their target price on Quest Diagnostics from $165.00 to $159.00 and set an “equal weight” rating for the company in a report on Friday, December 17th. Deutsche Bank Aktiengesellschaft raised their price target on Quest Diagnostics...
Read more ...

 

SRAX PT Raised to $13.50

SRAX PT Raised to $13.50

8 days ago   |   By ETF Daily News

SRAX had its target price raised by LADENBURG THALM/SH SH from $12.00 to $13.50 in a research report report published on Tuesday morning, The Fly reports.
Separately, Dawson James increased their price target on SRAX from $11.50 to $13.00 in a research note on Monday, January 10th.
Shares of SRAX opened at $5.36 on Tuesday. SRAX has a 52 week low of $2.91 and a 52 week high of $7.29. The company has a market cap of $140.16 million, a PE ratio of -6.09 and a beta of 1.89. The firm has a fifty day moving average price of $4.84.
SRAX last announced its quarterly earnings results on Monday...
Read more ...

 

ASGN Given New $150.00 Price Target at Truist

ASGN Given New $150.00 Price Target at Truist

8 days ago   |   By ETF Daily News

ASGN had its target price upped by Truist from $130.00 to $150.00 in a report released on Tuesday, The Fly reports.
Several other equities research analysts have also commented on ASGN. Robert W. Baird raised their price target on shares of ASGN from $117.00 to $122.00 and gave the company a neutral rating in a research note on Monday, September 27th. BMO Capital Markets raised their target price on shares of ASGN from $121.00 to $128.00 and gave the stock an outperform rating in a report on Thursday, September 16th. They noted that the move was a valuation call. Finally, Zacks Investment...
Read more ...

 

Truist Securities Trims Caesars Entertainment Target Price to $110.00

Truist Securities Trims Caesars Entertainment Target Price to $110.00

8 days ago   |   By ETF Daily News

Caesars Entertainment had its price target cut by Truist Securities from $140.00 to $110.00 in a research note published on Thursday, Stock Target Advisor reports. Truist Securities also issued estimates for Caesars Entertainment's Q1 2022 earnings at EPS.
A number of other equities analysts have also recently issued reports on the company. Stifel Nicolaus boosted their price objective on Caesars Entertainment from $130.00 to $138.00 and gave the company a buy rating in a report on Friday, October 8th. Citigroup initiated coverage on Caesars Entertainment in a research report on Tuesday...
Read more ...

 

Lululemon Athletica PT Lowered to $386.00 at Truist Securities

Lululemon Athletica PT Lowered to $386.00 at Truist Securities

8 days ago   |   By ETF Daily News

Lululemon Athletica had its price objective cut by Truist Securities from $435.00 to $386.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. Truist Securities also issued estimates for Lululemon Athletica's Q4 2022 earnings at $3.26 EPS, FY2022 earnings at $7.69 EPS, Q1 2023 earnings at $1.35 EPS, Q2 2023 earnings at $1.96 EPS, Q4 2023 earnings at $3.84 EPS, FY2023 earnings at $9.20 EPS and FY2024 earnings at $10.90 EPS.
Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft cut their price objective...
Read more ...

 

Albemarle PT Lowered to $280.00 at Citigroup

Albemarle PT Lowered to $280.00 at Citigroup

8 days ago   |   By ETF Daily News

Albemarle had its price target reduced by Citigroup from $323.00 to $280.00 in a research report report published on Tuesday morning, The Fly reports.
A number of other equities research analysts have also recently commented on ALB. Loop Capital lifted their target price on Albemarle from $253.00 to $280.00 and gave the stock a buy rating in a research note on Monday, October 4th. Deutsche Bank Aktiengesellschaft lifted their price objective on Albemarle from $245.00 to $270.00 and gave the stock a buy rating in a report on Monday, September 13th. Berenberg Bank raised Albemarle to a buy...
Read more ...

 

Scotiabank Trims B2Gold Target Price to C$8.00

Scotiabank Trims B2Gold Target Price to C$8.00

8 days ago   |   By ETF Daily News

B2Gold had its price objective decreased by Scotiabank from C$9.00 to C$8.00 in a research note issued to investors on Tuesday morning, The Fly reports.
Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut shares of B2Gold from a neutral rating to an underweight rating and set a $5.00 target price on the stock. in a research report on Friday, December 10th. Raymond James set a $6.50 price target on shares of B2Gold and gave the company an outperform rating in a report on Wednesday, November 3rd. Two research analysts have rated the...
Read more ...

 


Search by Tags

   Investments      Investment      Rate      Company      Security      Banks      Companies      Invest      Buy      Bank      Stocknews      Credits      Credit      Marketing      Market      Services      Moving      Business      Service      Data  


Once allies, Stormy Daniels and Avenatti face off at trial

Once allies, Stormy Daniels and Avenatti face off at trial

NEW YORK - Stormy Daniels, the porn star who catapulted herself and Michael Avenatti to fame with lawsuits against former President Donald Trump, will have a starring role in... Read more ...

Twitter users are comparing Elon Musk's Neuralink chip implants to a similar...

Elon Musk. Patrick Pleul/picture alliance via Getty Images Elon Musk is developing a brain implant for humans he formerly said may have the potential to "save and replay... Read more ...

RFK Jr., Lara Logan Speaking At Anti-Vaccine Mandate Protest In D.C

Notable speakers include anti-mandate proponents like Robert Kennedy Jr. Read more ...

Intel CEO reveals how he plans to rebuild the struggling chip industry by...

Intel CEO Patrick Gelsinger speaks alongside U.S. President Joe Biden during an event on the ongoing supply chain problems on January 21, 2022 in Washington, DC. Chip... Read more ...

Ethics and ownership of AI-powered identities

Ethics and ownership of AI-powered identities

People will soon be asked to decide how their voices, images, and AI-powered identities can be used both today and long after they're gone. Read more ...

Buccaneers Vs. Rams Schedule, Odds: Time, Bracket, Picks, Spread And NFL...

The Divisional round of the 2022 NFL playoffs gets underway again on Sunday afternoon when the Tampa Bay Buccaneers host the Los Angeles Rams. Read more ...

Taliban begin talks in Norway as hunger stalks Afghanistan

Taliban begin talks in Norway as hunger stalks Afghanistan

OSLO, Norway - A Taliban delegation led by acting Foreign Minister Amir Khan Muttaqi on Sunday started three days of talks in Oslo with Western officials and Afghan civil... Read more ...

Cruise ship changes course after US judge orders seizure

MIAMI - A cruise ship that was supposed to dock in Miami sailed to the Bahamas instead after a U.S. judge granted an order to seize the vessel as part of a lawsuit over unpaid... Read more ...

Yellowstone visits hit record high in 2021, straining staff

MAMMOTH HOT SPRINGS, Wyo. - A record number of visitors flocked to Yellowstone National Park last year despite fewer hotel rooms and campsites being available because of the... Read more ...

Recapping Aaron Rodgers' Wild NFL Season: Ivermectin, Miles Teller...

Aaron Rodgers was equally explosive on and off the field during the 2021 NFL season, earning the ire of many for misleading reporters about his Covid-19 vaccination status on... Read more ...